1-((4-methyl-1-(2-(1-methyl-1H-indol-5-ylamino)pyrimidin-4-yl)-1H-pyrrol-3-yl)methyl)azetidin-3-ol | 1307803-10-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-((4-methyl-1-(2-(1-methyl-1H-indol-5-ylamino)pyrimidin-4-yl)-1H-pyrrol-3-yl)methyl)azetidin-3-ol
• 英文别名: 1-[[4-Methyl-1-[2-[(1-methylindol-5-yl)amino]pyrimidin-4-yl]pyrrol-3-yl]methyl]azetidin-3-ol
• CAS: 1307803-10-6
• 化学式: C₂₂H₂₄N₆O
• 分子量: 388.472
• InChiKey: UBVUHNLTWFRDMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  71.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS<br/>[FR] COMPOSÉS DE TYPE PYRIMIDINE SUBSTITUÉE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DES KINASES SYK
  申请人：GENOSCO

  公开号：WO2013109882A1

  公开（公告）日：2013-07-25

  Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

  公式（I）的化合物和抑制激酶的方法被揭示。还揭示了通过向受试者投予公式（I）的化合物的治疗有效量来治疗激酶介导的疾病或病况的方法。
• Kinase Inhibitors
  申请人：Lee Jaekyoo

  公开号：US20110281841A1

  公开（公告）日：2011-11-17

  The present invention provides a new group of protein kinase inhibitors, pyrropyrimidine and pyrazolopyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof that are useful for treating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrropyrimidine and pyrazolopyrimidine derivatives.

  本发明提供了一种新的蛋白激酶抑制剂群，包括吡咯嘧啶和吡唑嘧啶衍生物，以及其药学上可接受的盐和前药，用于治疗细胞增殖性疾病和疾病，例如癌症、自身免疫性疾病、感染、心血管疾病和神经退行性疾病。本发明提供了合成和给药蛋白激酶抑制剂化合物的方法。本发明还提供了包含至少一种蛋白激酶抑制剂化合物和药学上可接受的载体、稀释剂或赋形剂的制剂。本发明还提供了在合成吡咯嘧啶和吡唑嘧啶衍生物的过程中产生的有用中间体。
• SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS
  申请人：OSCOTEC, INC.

  公开号：US20130274242A1

  公开（公告）日：2013-10-17

  Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

  本文披露了化学式(I)的化合物及其抑制酶，包括脾酪氨酸激酶的方法。同时还披露了通过向受试者施用化学式(I)化合物的治疗有效剂量来治疗酶介导的疾病或状况的方法。
• KINASE INHIBITORS
  申请人：Genosco

  公开号：EP2498607B1

  公开（公告）日：2016-02-17
• US8629132B2
  申请人：——

  公开号：US8629132B2

  公开（公告）日：2014-01-14